Plasma and Serum Alpha-Synuclein as a Biomarker of Diagnosis in Patients With Parkinson's Disease
| العنوان: | Plasma and Serum Alpha-Synuclein as a Biomarker of Diagnosis in Patients With Parkinson's Disease |
|---|---|
| المؤلفون: | Che-Chuan Yang, Shieh-Yueh Yang, Chun-Wei Chang, Chia-Wen Chang, Yih-Ru Wu |
| المصدر: | Frontiers in Neurology, Vol 10 (2020) Frontiers in Neurology |
| سنة النشر: | 2018 |
| مصطلحات موضوعية: | 0301 basic medicine, medicine.medical_specialty, Parkinson's disease, medicine.drug_class, Disease, immunomagnetic reduction, Monoclonal antibody, Gastroenterology, lcsh:RC346-429, Pathogenesis, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, α-synuclein, modified Hoehn and Yahr scale, Internal medicine, medicine, lcsh:Neurology. Diseases of the nervous system, Original Research, Alpha-synuclein, Receiver operating characteristic, business.industry, Venous blood, medicine.disease, nervous system diseases, Parkinson disease, 030104 developmental biology, Neurology, chemistry, nervous system, Biomarker (medicine), biomarker, Neurology (clinical), business, 030217 neurology & neurosurgery |
| الوصف: | Background: Parkinson's disease (PD) is the second most common neurodegenerative disease, and α-synuclein plays a critical role in the pathogenesis of PD. Studies have revealed controversial results regarding the correlation between motor severity and α-synuclein levels in peripheral blood from patients with PD. Objective: We examined α-synuclein levels in plasma or serum in patients with PD and investigated the relationship between plasma or serum α-synuclein level and motor symptom severity. Methods: We recruited 88 participants (48 patients with PD and 40 healthy controls). Clinical information was collected, and venous blood was drawn from each participant to be processed to obtain plasma or serum. The plasma or serum α-synuclein level was detected using monoclonal antibodies with magnetic nanoparticles, and was measured through immunomagnetic reduction. Plasma or serum α-synuclein levels were quantitatively detected. Results: In patients with PD, the means of plasma and serum α-synuclein level were 3.60 ± 2.53 and 0.03 ± 0.04 pg/mL, respectively. The areas under the receiver operating characteristic curve of plasma and serum α-synuclein for distinguishing patients with PD from healthy controls were 0.992 and 0.917, respectively. The serum α-synuclein level also showed a significant correlation with patients in H-Y stages 1–3 (r = 0.40, p = 0.025), implying that the serum α-synuclein level may be a potential marker of motor symptom severity in patients with early PD. Conclusions: Our data suggest that the α-synuclein level in serum or plasma can differentiate between healthy controls and patients with PD. Serum α-synuclein levels moderately correlate with motor severity in patients with early PD. |
| تدمد: | 1664-2295 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::558afb1234fb6cf707dce9e6a4a0a545Test https://pubmed.ncbi.nlm.nih.gov/32038461Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....558afb1234fb6cf707dce9e6a4a0a545 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 16642295 |
|---|